Coherus Biosciences Inc

-0.56 (-4.65%)
Products, Regulatory

Coherus And Junshi Biosciences Announce Positive Interim Results from Phase 3 Lung Cancer Therapy Clinical Trial

Published: 12/13/2021 14:03 GMT
Coherus Biosciences Inc (CHRS) - Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of Choice-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination With Chemotherapy As First-line Treatment for Non-small Cell Lung Cancer.
Coherus Biosciences Inc- Interim Analysis Showed Statistically Significant Improvement in Survival in Patients Treated With Toripalimab Plus Chemotherapy.
Coherus Biosciences - to Request FDA Meeting for Bla Supplement Submission for Toripalimab With Chemotherapy for First-line Treatment of Advanced Nsclc.